1] Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario M5G 2M9, Canada [2].
Princess Margaret Cancer Centre, University Health Network (UHN), Toronto, Ontario M5G 2M9, Canada.
Nature. 2014 Feb 20;506(7488):328-33. doi: 10.1038/nature13038. Epub 2014 Feb 12.
In acute myeloid leukaemia (AML), the cell of origin, nature and biological consequences of initiating lesions, and order of subsequent mutations remain poorly understood, as AML is typically diagnosed without observation of a pre-leukaemic phase. Here, highly purified haematopoietic stem cells (HSCs), progenitor and mature cell fractions from the blood of AML patients were found to contain recurrent DNMT3A mutations (DNMT3A(mut)) at high allele frequency, but without coincident NPM1 mutations (NPM1c) present in AML blasts. DNMT3A(mut)-bearing HSCs showed a multilineage repopulation advantage over non-mutated HSCs in xenografts, establishing their identity as pre-leukaemic HSCs. Pre-leukaemic HSCs were found in remission samples, indicating that they survive chemotherapy. Therefore DNMT3A(mut) arises early in AML evolution, probably in HSCs, leading to a clonally expanded pool of pre-leukaemic HSCs from which AML evolves. Our findings provide a paradigm for the detection and treatment of pre-leukaemic clones before the acquisition of additional genetic lesions engenders greater therapeutic resistance.
在急性髓系白血病(AML)中,起源细胞、起始病变的性质和生物学后果,以及随后突变的顺序仍知之甚少,因为 AML 通常是在没有观察到白血病前期阶段的情况下诊断出来的。在这里,从 AML 患者的血液中分离出高度纯化的造血干细胞(HSCs)、祖细胞和成熟细胞部分,发现它们以高等位基因频率携带复发性 DNMT3A 突变(DNMT3A(mut)),但不存在 AML blasts 中存在的 NPM1 突变(NPM1c)。DNMT3A(mut)-携带的 HSCs 在异种移植中显示出多谱系再增殖优势,超过非突变的 HSCs,证明它们是白血病前的 HSCs。在缓解样本中发现了白血病前 HSCs,表明它们在化疗后存活下来。因此,DNMT3A(mut)在 AML 进化的早期出现,可能在 HSCs 中出现,导致从其中进化出 AML 的白血病前 HSCs 克隆扩增。我们的研究结果为在获得更多遗传病变导致更大的治疗耐药性之前,检测和治疗白血病前克隆提供了范例。